MAQS advises Oblique Therapeutics in its issue of convertible bonds of approximately SEK 15.2 million

Oblique Therapeutics AB (publ) carries out an issue of convertible bonds which, upon ull subscription, will provide the company with proceeds of approximately SEK 15.2 million before deduction of costs related to the issue.

Oblique Therapeutics is a biotech company focused on developing antibody-based therapies to address significant unmet medical needs in chronic pain indications. The company aims to improve patients' quality of life through pioneering research and innovative solutions.

MAQS acts as legal advisor and Eminova Partners Corporate Finance AB acts as financial advisor to the company in connection with the issue. The MAQS team mainly consists of Anna Björk Larson and Fredrik Brusberg.